<p>加利福尼亚州布里斯班，2025 年 12 月 16 日（GLOBE NEWSWIRE）-- Annexon, Inc.（“Annexon”）（纳斯达克：ANNX）是一家生物制药公司，正在推进针对神经炎症的晚期临床平台，旨在治疗影响身体、大脑和眼睛的改变生活的补体介导疾病。今天宣布，根据 2022 年就业诱导奖励计划的条款，已向一名新的非执行员工授予诱导奖励。该股权奖励于 2025 年 12 月 10 日获得批准，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>这名新的非执行员工获得了购买 19,000 股 Annexon 普通股的期权。该期权的有效期为十年，每股行使价格为 4.91 美元，这是在 2025 年 12 月 15 日授予日 Annexon 普通股的收盘价，并且在 4 年内逐步归属，其中 25% 的期权所对应的股份在授予日的第一周年时归属，之后每月归属额外的 1/48 股份，前提是员工在适用的归属日期继续服务。</p>
<p><strong>关于 Annexon</strong></p>
<p>Annexon, Inc.（纳斯达克：ANNX）正在开发下一代补体抑制剂，以阻止神经炎症，作为针对数百万患有严重神经炎症疾病的患者的首创治疗方案。我们新颖的科学方法专注于 C1q，这是经典补体强效炎症通路的起始分子，当其方向错误时可能导致组织损伤和多种疾病的发生。通过靶向 C1q，我们的免疫疗法旨在在神经炎症级联反应开始之前阻止其发生。我们的产品管线涵盖三个不同的治疗领域——自身免疫、神经退行性疾病和眼科——包括旨在满足全球近 1000 万患者未满足需求的靶向研究药物候选者。Annexon 的使命是为患者提供改变游戏规则的疗法，使他们能够过上最佳生活。欲了解更多信息，请访问 annexonbio.com。</p>
<p><strong>投资者联系：</strong></p>
<p>乔伊斯·阿莱尔</p>
<p>LifeSci Advisors</p>
<p>jallaire@lifesciadvisors.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd016UXpOeU0zTXpJMU1USTVJekl4T1RBd09UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd016UXpOeU0zTXpJMU1USTVJekl4T1RBd09UST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjI0OTYwNzgtNDEzYi00NzgwLWIzZWQtZTA2ODg2YTU0Y2M0LTEyMDE2NDUtMjAyNS0xMi0xNy1lbg==/tiny/Annexon-Biosciences.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjI0OTYwNzgtNDEzYi00NzgwLWIzZWQtZTA2ODg2YTU0Y2M0LTEyMDE2NDUtMjAyNS0xMi0xNy1lbg==/tiny/Annexon-Biosciences.png"/></p>

ANNX

<p>Annexon, Inc. 宣布根据 2022 年就业诱导奖励计划向一名新非执行员工授予诱导奖励，符合纳斯达克上市规则 5635(c)(4)。该员工获得了以每股 4.91 美元购买 19,000 股普通股的期权，期权将在四年内逐步归属。Annexon 专注于开发用于神经炎症疾病的补体抑制剂</p>

<p>BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>加利福尼亚州布里斯班，2025 年 12 月 16 日（GLOBE NEWSWIRE）-- Annexon, Inc.（“Annexon”）（纳斯达克：ANNX）是一家生物制药公司，正在推进针对神经炎症的晚期临床平台，旨在治疗影响身体、大脑和眼睛的改变生活的补体介导疾病。今天宣布，根据 2022 年就业诱导奖励计划的条款，已向一名新的非执行员工授予诱导奖励。该股权奖励于 2025 年 12 月 10 日获得批准，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The new non-executive employee received an option to purchase 19,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $4.91, which was the closing price of Annexon’s common stock on December 15, 2025, the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.</p>
<div class="lb-trans"><p>这名新的非执行员工获得了购买 19,000 股 Annexon 普通股的期权。该期权的有效期为十年，每股行使价格为 4.91 美元，这是在 2025 年 12 月 15 日授予日 Annexon 普通股的收盘价，并且在 4 年内逐步归属，其中 25% 的期权所对应的股份在授予日的第一周年时归属，之后每月归属额外的 1/48 股份，前提是员工在适用的归属日期继续服务。</p>
</div><p><strong>About Annexon</strong></p>
<div class="lb-trans"><p><strong>关于 Annexon</strong></p>
</div><p>Annexon, Inc. (Nasdaq: ANNX) is developing the next generation of complement inhibitors to stop neuroinflammation as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss in a host of diseases. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade before it starts. Our pipeline spans three diverse therapeutic areas – autoimmunity, neurodegeneration and ophthalmology – and includes targeted investigational drug candidates designed to address the unmet needs of nearly 10 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.</p>
<div class="lb-trans"><p>Annexon, Inc.（纳斯达克：ANNX）正在开发下一代补体抑制剂，以阻止神经炎症，作为针对数百万患有严重神经炎症疾病的患者的首创治疗方案。我们新颖的科学方法专注于 C1q，这是经典补体强效炎症通路的起始分子，当其方向错误时可能导致组织损伤和多种疾病的发生。通过靶向 C1q，我们的免疫疗法旨在在神经炎症级联反应开始之前阻止其发生。我们的产品管线涵盖三个不同的治疗领域——自身免疫、神经退行性疾病和眼科——包括旨在满足全球近 1000 万患者未满足需求的靶向研究药物候选者。Annexon 的使命是为患者提供改变游戏规则的疗法，使他们能够过上最佳生活。欲了解更多信息，请访问 annexonbio.com。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>Joyce Allaire</p>
<div class="lb-trans"><p>乔伊斯·阿莱尔</p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>jallaire@lifesciadvisors.com</p>
<div class="lb-trans"><p>jallaire@lifesciadvisors.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd016UXpOeU0zTXpJMU1USTVJekl4T1RBd09UST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMzQzNyM3MzI1MTI5IzIxOTAwOTI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MjI0OTYwNzgtNDEzYi00NzgwLWIzZWQtZTA2ODg2YTU0Y2M0LTEyMDE2NDUtMjAyNS0xMi0xNy1lbg==/tiny/Annexon-Biosciences.png" alt="" original-src="https://ml.globenewswire.com/media/MjI0OTYwNzgtNDEzYi00NzgwLWIzZWQtZTA2ODg2YTU0Y2M0LTEyMDE2NDUtMjAyNS0xMi0xNy1lbg==/tiny/Annexon-Biosciences.png"/></p>

Annexon 根据纳斯达克上市规则 5635(c)(4) 报告向新员工授予激励措施 | ANNX 股票新闻